FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Stem Cells Int / Intra-Articular Injection of 2 Different Dosages of Autologo...
Stem cells international2019; 2019; 9431894; doi: 10.1155/2019/9431894

Intra-Articular Injection of 2 Different Dosages of Autologous and Allogeneic Bone Marrow- and Umbilical Cord-Derived Mesenchymal Stem Cells Triggers a Variable Inflammatory Response of the Fetlock Joint on 12 Sound Experimental Horses.

Abstract: Osteoarthritis is a significant and costly cause of pain for both humans and horses. The horse has been identified as a suitable model for human osteoarthritis. Regenerative therapy with allogeneic mesenchymal stem cells (MSCs) is a promising treatment, but the safety of this procedure continues to be debated. The aim of this study is to evaluate the safety of intra-articular injections of allogeneic MSCs on healthy joints by comparing two different dosages and two different tissue sources, namely, bone marrow and umbilical cord blood, with a placebo treatment on the same individuals. We also assessed the influence of autologous versus allogeneic cells for bone marrow-derived MSC treatment. Twelve clinically sound horses were subjected to injections in their 4 fetlock joints. Each of the three fetlocks was administered a different MSC type, and the remaining fetlock was injected with phosphate-buffered saline as a control. Six horses received 10 million cells per joint, and the 6 other horses received 20 million cells per joint. Clinical and ultrasound monitoring revealed that allogeneic bone marrow-derived MSCs induced significantly more synovial effusion compared to umbilical cord blood-derived MSCs but no significant difference was noted within the synovial fluid parameters. The administration of 10 million cells in horses triggered significantly more inflammatory signs than the administration of 20 million cells. Mesenchymal stem cell injections induced mild to moderate local inflammatory signs compared to the placebo, with individual variability in the sensitivity to the same line of MSCs. Understanding the behavior of stem cells when injected alone is a step towards the safer use of new strategies in stem cell therapy, where the use of either MSC secretome or MSCs combined with biomaterials could enhance their viability and metabolic activity.
Get Full Text
Publication Date: 2019-05-02 PubMed ID: 31191689PubMed Central: PMC6525957DOI: 10.1155/2019/9431894Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article investigates the safety of using two different types of mesenchymal stem cells (MSCs) and two different dosages for treating osteoarthritis in horses. The study used 12 healthy horses and noted a variable inflammatory response, raising questions on the safety of such procedures.

Methodology of the Study

  • The study involved 12 clinically sound horses with healthy joints.
  • Each of the four fetlock joints of the horses were injected with different treatments. Three joints received different types of MSCs, namely, autologous and allogeneic bone marrow-, and umbilical cord-derived MSCs. The fourth joint was injected with phosphate-buffered saline as a control.
  • The horses were split into two groups. Six horses received 10 million cells per joint, while the remaining six received 20 million cells per joint.

Findings of the Study

  • It was found that all types of stem cell injections induced some degree of local inflammatory response when compared to the control injection.
  • The use of allogeneic bone marrow-derived MSCs caused significantly more synovial effusion when compared to MSCs derived from umbilical cord blood.
  • There was no significant difference in the synovial fluid parameters across different treatments.
  • Interestingly, the administration of a lower dosage (10 million cells) triggered more local inflammatory signs than the higher dosage (20 million cells).
  • There was also a noticeable individual variability in the response to the same type of MSCs, raising questions on the predictability and safety of the procedure.

Implications of the Findings

  • This study raises important questions on the safety and effectiveness of using MSCs for regenerative therapy in osteoarthritis, especially considering the variable inflammatory response.
  • The findings will provide useful insights into the behavior of stem cells when injected alone, which could help in improving the safety of stem cell therapies.
  • The study could also pave the way for new strategies in stem cell therapy. These might involve using the secretome of MSCs or combining MSCs with biomaterials to enhance viability and metabolic activity.

Cite This Article

APA
Bertoni L, Branly T, Jacquet S, Desancé M, Desquilbet L, Rivory P, Hartmann DJ, Denoix JM, Audigié F, Galéra P, Demoor M. (2019). Intra-Articular Injection of 2 Different Dosages of Autologous and Allogeneic Bone Marrow- and Umbilical Cord-Derived Mesenchymal Stem Cells Triggers a Variable Inflammatory Response of the Fetlock Joint on 12 Sound Experimental Horses. Stem Cells Int, 2019, 9431894. https://doi.org/10.1155/2019/9431894

Publication

Stem cells international
ISSN: 1687-966X
NlmUniqueID: 101535822
Country: United States
Language: English
Volume: 2019
Pages: 9431894

Researcher Affiliations

Bertoni, Lélia
  • CIRALE, USC 957, BPLC, INRA, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort F-94700, France.
Branly, Thomas
  • Normandie University, UNICAEN, BIOTARGEN, 14000 Caen, France.
Jacquet, Sandrine
  • CIRALE, USC 957, BPLC, INRA, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort F-94700, France.
Desancé, Mélanie
  • Normandie University, UNICAEN, BIOTARGEN, 14000 Caen, France.
Desquilbet, Loïc
  • U955-IMRB, Inserm, Ecole Nationale Vétérinaire d'Alfort, UPEC, Maisons-Alfort F-94700, France.
Rivory, Pascaline
  • NOVOTEC, ZAC du Chêne, Europarc, 69500 Bron, France.
Hartmann, Daniel-Jean
  • NOVOTEC, ZAC du Chêne, Europarc, 69500 Bron, France.
Denoix, Jean-Marie
  • CIRALE, USC 957, BPLC, INRA, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort F-94700, France.
Audigié, Fabrice
  • CIRALE, USC 957, BPLC, INRA, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort F-94700, France.
Galéra, Philippe
  • Normandie University, UNICAEN, BIOTARGEN, 14000 Caen, France.
Demoor, Magali
  • Normandie University, UNICAEN, BIOTARGEN, 14000 Caen, France.

References

This article includes 50 references
  1. Schlueter AE, Orth MW. Equine osteoarthritis: a brief review of the disease and its causes.. Equine and Comparative Exercise Physiology 2004;1(4):221–231.
    doi: 10.1079/ECP200428google scholar: lookup
  2. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse – a review.. Veterinary Journal 2006;171(1):51–69.
    doi: 10.1016/j.tvjl.2004.07.008pubmed: 16427582google scholar: lookup
  3. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis.. Bone & Joint Research 2012;1(11):297–309.
    doi: 10.1302/2046-3758.111.2000132pmc: PMC3626203pubmed: 23610661google scholar: lookup
  4. Frisbie DD. Future directions in treatment of joint disease in horses.. Veterinary Clinics of North America: Equine Practice 2005;21(3):713–724.
    doi: 10.1016/j.cveq.2005.07.001pubmed: 16297729google scholar: lookup
  5. Thiede RM, Lu Y, Markel MD. A review of the treatment methods for cartilage defects.. Veterinary and Comparative Orthopaedics and Traumatology 2012;25(4):263–272.
    doi: 10.3415/VCOT-11-05-0070pubmed: 22286150google scholar: lookup
  6. Vézina Audette R, Lavoie-Lamoureux A, Lavoie J-P, Laverty S. Inflammatory stimuli differentially modulate the transcription of paracrine signaling molecules of equine bone marrow multipotent mesenchymal stromal cells.. Osteoarthritis and Cartilage 2013;21(8):1116–1124.
    doi: 10.1016/j.joca.2013.05.004pubmed: 23685224google scholar: lookup
  7. Carrade DD, Borjesson DL. Immunomodulation by mesenchymal stem cells in veterinary species.. Comparative Medicine 2013;63(3):207–217.
    pmc: PMC3690426pubmed: 23759523
  8. Ursini TL, Amelse LL, Elkhenany HA. Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses.. Equine Veterinary Journal 2019;51(2):198–205.
    doi: 10.1111/evj.12992pubmed: 29992618google scholar: lookup
  9. Ferris DJ, Frisbie DD, Kisiday JD. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.. Veterinary Surgery 2014;43(3):255–265.
    doi: 10.1111/j.1532-950X.2014.12100.xpubmed: 24433318google scholar: lookup
  10. Schnabel LV, Fortier LA, Wayne McIlwraith C, Nobert KM. Therapeutic use of stem cells in horses: which type, how, and when?. Veterinary Journal 2013;197(3):570–577.
    doi: 10.1016/j.tvjl.2013.04.018pubmed: 23778257google scholar: lookup
  11. Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro.. Stem Cell Research & Therapy 2014;5(4):p. 90.
    doi: 10.1186/scrt479pmc: PMC4247727pubmed: 25080326google scholar: lookup
  12. Broeckx S, Zimmerman M, Crocetti S. Regenerative therapies for equine degenerative joint disease: a preliminary study.. PLoS One 2014;9(1, article e85917).
    doi: 10.1371/journal.pone.0085917pmc: PMC3896436pubmed: 24465787google scholar: lookup
  13. Guest DJ, Smith MRW, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study.. Equine Veterinary Journal 2008;40(2):178–181.
    doi: 10.2746/042516408X276942pubmed: 18267891google scholar: lookup
  14. Carrade DD, Affolter VK, Outerbridge CA. Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions.. Cytotherapy 2011;13(10):1180–1192.
    doi: 10.3109/14653249.2011.602338pubmed: 21899391google scholar: lookup
  15. Ardanaz N, Vázquez FJ, Romero A. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints.. BMC Veterinary Research 2016;12(1):p. 65.
    doi: 10.1186/s12917-016-0692-xpmc: PMC4815220pubmed: 27029614google scholar: lookup
  16. Carrade DD, Owens SD, Galuppo LD. Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses.. Cytotherapy 2011;13(4):419–430.
    doi: 10.3109/14653249.2010.536213pubmed: 21105841google scholar: lookup
  17. Pig JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. Inflammatory effects of autologous, genetically modified autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.. Veterinary and Comparative Orthopaedics and Traumatology 2013;26(6):453–460.
    doi: 10.3415/VCOT-13-01-0008pubmed: 24080668google scholar: lookup
  18. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJB, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro .. Stem Cell Research & Therapy 2014;5(1):p. 13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  19. Pezzanite LM, Fortier LA, Antczak DF. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Research & Therapy 2015;6(1):p. 54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup
  20. Joswig AJ, Mitchell A, Cummings KJ. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model.. Stem Cell Research & Therapy 2017;8(1):p. 42.
    doi: 10.1186/s13287-017-0503-8pmc: PMC5329965pubmed: 28241885google scholar: lookup
  21. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Veterinary Journal 2017;49(4):539–544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  22. Broeckx SY, Spaas JH, Chiers K. Equine allogeneic chondrogenic induced mesenchymal stem cells: a GCP target animal safety and biodistribution study.. Research in Veterinary Science 2018;117:246–254.
    doi: 10.1016/j.rvsc.2017.12.018pubmed: 29329028google scholar: lookup
  23. Lee WY, Wang B. Cartilage repair by mesenchymal stem cells: clinical trial update and perspectives.. Journal of Orthopaedic Translation 2017;9:76–88.
    doi: 10.1016/j.jot.2017.03.005pmc: PMC5822962pubmed: 29662802google scholar: lookup
  24. Lang HM, Schnabel LV, Cassano JM, Fortier LA. Effect of needle diameter on the viability of equine bone marrow derived mesenchymal stem cells.. Veterinary Surgery 2017;46(5):731–737.
    doi: 10.1111/vsu.12639pmc: PMC5493497pubmed: 28328147google scholar: lookup
  25. Orsini JA, Divers TJ. Manual of Equine Emergencies: Treatment and Procedures.. WB Saunders; 2003.
  26. Branly T, Bertoni L, Contentin R. Characterization and use of equine bone marrow mesenchymal stem cells in equine cartilage engineering. Study of their hyaline cartilage forming potential when cultured under hypoxia within a biomaterial in the presence of BMP-2 and TGF-ß1.. Stem Cell Reviews and Reports 2017;13(5):611–630.
    doi: 10.1007/s12015-017-9748-ypubmed: 28597211google scholar: lookup
  27. Branly T, Contentin R, Desancé M. Improvement of the chondrocyte-specific phenotype upon equine bone marrow mesenchymal stem cell differentiation: influence of culture time, transforming growth factors and type I collagen siRNAs on the differentiation index.. International Journal of Molecular Sciences 2018;19(2):p. 435.
    doi: 10.3390/ijms19020435pmc: PMC5855657pubmed: 29389887google scholar: lookup
  28. Bartholomew S, Owens SD, Ferraro GL. Collection of equine cord blood and placental tissues in 40 thoroughbred mares.. Equine Veterinary Journal 2009;41(8):724–728.
    doi: 10.2746/042516409X429446pubmed: 20095217google scholar: lookup
  29. Desancé M, Contentin R, Bertoni L. Chondrogenic differentiation of defined equine mesenchymal stem cells derived from umbilical cord blood for use in cartilage repair therapy.. International Journal of Molecular Sciences 2018;19(2):p. 537.
    doi: 10.3390/ijms19020537pmc: PMC5855759pubmed: 29439436google scholar: lookup
  30. Bronzini I, Patruno M, Iacopetti I, Martinello T. Influence of temperature, time and different media on mesenchymal stromal cells shipped for clinical application.. Veterinary Journal 2012;194(1):121–123.
    doi: 10.1016/j.tvjl.2012.03.010pubmed: 22503718google scholar: lookup
  31. American Association of Equine Practitioners AA of EP. Guide for Veterinary Service and Judging of Equestrian Events.. Lexington: AAEP; 1991.
  32. Jing X, Yang L, Duan X. In vivo MR imaging tracking of magnetic iron oxide nanoparticle labeled, engineered, autologous bone marrow mesenchymal stem cells following intra-articular injection.. Joint, Bone, Spine 2008;75(4):432–438.
    doi: 10.1016/j.jbspin.2007.09.013pubmed: 18448377google scholar: lookup
  33. Bertone AL, Palmer JL, Jones J. Synovial fluid cytokines and eicosanoids as markers of joint disease in horses.. Veterinary Surgery 2001;30(6):528–538.
    doi: 10.1053/jvet.2001.28430pubmed: 11704948google scholar: lookup
  34. Christgau S, Garnero P, Fledelius C. Collagen type II C-telopeptide fragments as an index of cartilage degradation.. Bone 2001;29(3):209–215.
    doi: 10.1016/S8756-3282(01)00504-Xpubmed: 11557363google scholar: lookup
  35. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes.. Biometrics 1986;42(1):121–130.
    doi: 10.2307/2531248pubmed: 3719049google scholar: lookup
  36. Pers Y-M, Rackwitz L, Ferreira R. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial.. Stem Cells Translational Medicine 2016;5(7):847–856.
    doi: 10.5966/sctm.2015-0245pmc: PMC4922848pubmed: 27217345google scholar: lookup
  37. Duclos ME, Roualdes O, Cararo R, Rousseau JC, Roger T, Hartmann DJ. Significance of the serum CTX-II level in an osteoarthritis animal model: a 5-month longitudinal study.. Osteoarthritis and Cartilage 2010;18(11):1467–1476.
    doi: 10.1016/j.joca.2010.07.007pubmed: 21056352google scholar: lookup
  38. Oliveira E, Assunção-Silva RC, Ziv-Polat O. Influence of different ECM-like hydrogels on neurite outgrowth induced by adipose tissue-derived stem cells.. Stem Cells International 2017;2017:10.
    doi: 10.1155/2017/6319129pmc: PMC5733162pubmed: 29333166google scholar: lookup
  39. Silva NA, Moreira J, Ribeiro-Samy S. Modulation of bone marrow mesenchymal stem cell secretome by ECM-like hydrogels.. Biochimie 2013;95(12):2314–2319.
    doi: 10.1016/j.biochi.2013.08.016pubmed: 23994751google scholar: lookup
  40. Cheng L, Zhang K, Wu S, Cui M, Xu T. Focus on mesenchymal stem cell-derived exosomes: opportunities and challenges in cell-free therapy.. Stem Cells International 2017;2017:10.
    doi: 10.1155/2017/6305295pmc: PMC5749272pubmed: 29410682google scholar: lookup
  41. Morton AJ. Diagnosis and treatment of septic arthritis.. Veterinary Clinics of North America: Equine Practice 2005;21(3):627–649.
    doi: 10.1016/j.cveq.2005.08.001pubmed: 16297725google scholar: lookup
  42. Hill JA, Cassano JM, Goodale MB, Fortier LA. Antigenicity of mesenchymal stem cells in an inflamed joint environment.. American Journal of Veterinary Research 2017;78(7):867–875.
    doi: 10.2460/ajvr.78.7.867pubmed: 28650243google scholar: lookup
  43. Bertone A. Noninfectious arthritis.. In: Ross MW, Dyson SJ, editors. Diagnosis and Management of Lameness in the Horse. 2nd. St. Louis, Missouri: Elsevier; 2011. pp. 657–690.
    doi: 10.1016/B978-1-4160-6069-7.00066-3google scholar: lookup
  44. Barrachina L, Remacha AR, Romero A. Inflammation affects the viability and plasticity of equine mesenchymal stem cells: possible implications in intra-articular treatments.. Journal of Veterinary Science 2017;18(1):39–49.
    doi: 10.4142/jvs.2017.18.1.39pmc: PMC5366301pubmed: 27297420google scholar: lookup
  45. Boone L, Mumaw J, Thoresen M, Gogal R, Peroni J. Viability, proliferation, and chondrogenesis of equine bone marrow–derived mesenchymal stromal cells after exposure to varying concentrations of allogeneic synovial fluid in vitro.. Journal of Equine Veterinary Science 2018;62:1–7.
    doi: 10.1016/j.jevs.2017.10.019google scholar: lookup
  46. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells.. Blood 2007;110(10):3499–3506.
    doi: 10.1182/blood-2007-02-069716pubmed: 17664353google scholar: lookup
  47. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications.. Stem Cell Research & Therapy 2010;1(1):p. 2.
    doi: 10.1186/scrt2pmc: PMC2873698pubmed: 20504283google scholar: lookup
  48. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells.. Cell Medicine 2012;4(1):1–12.
    doi: 10.3727/215517912X647217pmc: PMC3495591pubmed: 23152950google scholar: lookup
  49. Karp JM, Teo GSL. Mesenchymal stem cell homing: the devil is in the details.. Cell Stem Cell 2009;4(3):206–216.
    doi: 10.1016/j.stem.2009.02.001pubmed: 19265660google scholar: lookup
  50. Nishijima T. The fine structure of the synovial membrane of the knee joint in rats with special reference to regional differences.. Nihon Seikeigeka Gakkai Zasshi 1981;55(6):601–613.
    pubmed: 7310206
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.